Valneva and BliNK Therapeutics confirm launch and funding of BliNK Biomedical

European biotechnology company Valneva SE ("Valneva") and UK company BliNK Therapeutics Ltd ("BliNK Therapeutics") announced today the closing of the transaction creating BliNK Biomedical SAS, a private company specialised in the discovery of innovative monoclonal antibodies. 

  • 20 January 2015

The new company is owned by Valneva, Kurma Biofund I (founding investor of BliNK Therapeutics), funds managed by Idinvest Partners, Cancer Research Technology (CRT) and BliNK Therapeutics’ founders.

BliNK Therapeutics’ technology has been developed by Facundo Batista, Head of the Lymphocyte Interaction Laboratory at Cancer Research UK's London Research Institute.

Related content

STORM Therapeutics logo

STORM Therapeutics to present promising Phase 1 sarcoma data demonstrating activity of First‑in‑Class METTL3 inhibitor STC‑15 at ASCO 2026

STORM Therapeutics Ltd., the clinical stage company targeting RNA modifications to reprogram cells and develop novel cancer therapies, announces that a subset analysis of sarcoma patients enrolled in the Phase 1 dose escalation study of its lead candidate, STC‑15, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026 in Chicago, Illinois.